<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04658251</url>
  </required_header>
  <id_info>
    <org_study_id>2020_66</org_study_id>
    <secondary_id>2020-A02559-30</secondary_id>
    <nct_id>NCT04658251</nct_id>
  </id_info>
  <brief_title>Study of New Mutations in Cone Disorders</brief_title>
  <acronym>INTROCONE</acronym>
  <official_title>Functional Study of Intronic Variants in Inherited Cone Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Lille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      High throughput sequencing gives the opportunity to improve the genetic diagnosis for&#xD;
      patients suffering from retinal dystrophies and specially from cone disorders. However, a&#xD;
      large number of mutations are identified, mostly in introns of the genes, and in silico&#xD;
      analysis are not sufficient to assign the pathogenicity of these mutations, without which the&#xD;
      diagnosis confirmation cannot be done. For that purpose, a functional analysis of intronic&#xD;
      variants of unknown significance detected in patients, with minigene splice assays in&#xD;
      parallel with the analysis of the effect of the variant on splicing directly in the cells of&#xD;
      the patient, by analyzing the RNA from leucocytes, fibroblasts, lymphoblasto√Ød cells or&#xD;
      precursor of photoreceptor cells, which is the only proof of pathogenicity for variants&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 3, 2021</start_date>
  <completion_date type="Anticipated">March 2024</completion_date>
  <primary_completion_date type="Anticipated">March 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of the intronic variant on RNA splicing observed in cellulo and/or on patient cells,</measure>
    <time_frame>at 2 years</time_frame>
    <description>Analysis of RNA transcripts of the gene carrying a variant of unknown significance.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of the intronic variant on RNA by Minigene splice assay in transient cell cultures</measure>
    <time_frame>at 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of the intronic variant on RNA by analysis of patient RNA transcripts</measure>
    <time_frame>at 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of the intronic variant on RNA by analysis of transcripts from fibroblasts</measure>
    <time_frame>at 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of the intronic variant on RNA by analysis of transcripts from lymphoblastoid lines</measure>
    <time_frame>at 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of the intronic variant on RNA by analysis of transcripts from IPSCs (induced pluripotent stem cells)</measure>
    <time_frame>at 2 years</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Retinal Dystrophy, Cone-Rod</condition>
  <condition>Cone Dystrophy</condition>
  <condition>Cone Rod Dystrophy</condition>
  <condition>Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>Patients with an intronic variant unknown in a gene implicated in cone disorders.</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Blood and/or skin biopsy</intervention_name>
    <description>Blood and/or skin biopsy will be withdrawn, for RNA extraction in order to test the effect of the variant on splicing.</description>
    <arm_group_label>Patients with an intronic variant unknown in a gene implicated in cone disorders.</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples:&#xD;
&#xD;
        -  Paxgen tubes (2 x 5ml) and heparin tubes (2 x 7ml) will be collected (maximum 32 ml) for&#xD;
           RNA extraction if the candidate gene is expressed in the leucocytes&#xD;
&#xD;
        -  Potentially 2 Vacutainer CPT tubes for IPSC generation&#xD;
&#xD;
      Biopsy:&#xD;
&#xD;
      Potentially a skin biopsy (3 mm diameter) will be carried out if the gene is not expressed in&#xD;
      leucocytes&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients carrying an intronic variant of unknown significance (or carrying an exonic&#xD;
        variant with a predicted effect on splicing) in a gene implicated (or potentially&#xD;
        implicated) in cone disorders, will be included in the study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  clinical diagnosis of cone disorder&#xD;
&#xD;
          -  identification of a variant of unknown significance&#xD;
&#xD;
          -  possibility of samplings&#xD;
&#xD;
          -  informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  no variant of unknown significance identified&#xD;
&#xD;
          -  no informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claire-Marie DHAENENS, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Lille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Claire-Marie DHAENENS, MD</last_name>
    <phone>0320445962</phone>
    <phone_ext>+33</phone_ext>
    <email>claire-marie.dhaenens@chru-lille.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU lille</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>0320445962</phone>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>December 1, 2020</study_first_submitted>
  <study_first_submitted_qc>December 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 8, 2020</study_first_posted>
  <last_update_submitted>April 27, 2021</last_update_submitted>
  <last_update_submitted_qc>April 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>intronic variant</keyword>
  <keyword>splicing</keyword>
  <keyword>functional test</keyword>
  <keyword>cone disorders</keyword>
  <keyword>retinal dystrophy</keyword>
  <keyword>RNA</keyword>
  <keyword>minigene splice assay</keyword>
  <keyword>cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Retinal Dystrophies</mesh_term>
    <mesh_term>Cone Dystrophy</mesh_term>
    <mesh_term>Cone-Rod Dystrophies</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

